Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia
- 9 November 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 27 (6), 1411-1413
- https://doi.org/10.1038/leu.2012.324
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Management of Philadelphia chromosome-positive acute lymphoblastic leukemiaLeukemia Supplements, 2012
- Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemiaOncoImmunology, 2012
- Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonistLeukemia, 2011
- Philadelphia chromosome‐positive acute lymphoblastic leukemiaCancer, 2010
- Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantationBone Marrow Transplantation, 2009
- Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyPublished by American Society of Hematology ,2007
- Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALLNew England Journal of Medicine, 2006
- AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid LeukemiaClinical Cancer Research, 2005
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell, 2005
- Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatmentLeukemia, 2003